All stock lists
Alx Oncology Holdings Inc (NASDAQ:ALXO)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.14
Insider Score
––Not scored
ALXO Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ALXO analyst forecast
Best analysts covering ALXO
- HC Wainwright & Co.29%success rate · 14 calls
- Piper Sandler20%success rate · 5 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ALXO analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-10 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-02-05 |
| — | UBS | Buy | — | — | Reiterated | 2025-05-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-07 |
| — | Stifel | Hold | — | — | Reiterated | 2025-03-07 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-03-06 |
| — | Jefferies | Buy | — | — | Upgraded | 2025-03-06 |
| — | UBS | Buy | — | — | Reiterated | 2025-01-27 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-01-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-24 |
| — | Jefferies | Hold | — | — | Downgraded | 2024-12-19 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-12-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-18 |
| — | UBS | Buy | — | — | Reiterated | 2024-08-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-13 |
| — | Stifel | Hold | — | — | Reiterated | 2024-08-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-01 |
| — | Stifel | Hold | — | — | Reiterated | 2024-08-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-11 |
| — | Stifel | Hold | — | — | Downgraded | 2024-03-08 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-03-08 |
| — | Jefferies | Buy | — | — | Upgraded | 2023-12-08 |
| — | Stifel | Buy | — | — | Reiterated | 2023-11-14 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-10-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-10-04 |
| — | UBS | Buy | — | — | Reiterated | 2023-10-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-10-03 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-09-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-08-11 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-08-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-07-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-12 |
| — | UBS | Buy | — | — | Reiterated | 2023-03-15 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-03-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-11-09 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2022-08-09 |
| — | Stifel | Buy | — | — | Reiterated | 2022-06-06 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-05-19 |
| — | Stifel | Buy | — | — | Reiterated | 2022-03-01 |
| — | Jefferies | Hold | — | — | Downgraded | 2021-12-22 |
| — | Stifel | Buy | — | — | Reiterated | 2021-09-30 |
| — | UBS | Buy | — | — | Reiterated | 2021-04-06 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2021-02-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-02-10 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2020-08-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2020-08-11 |
| — | Jefferies | Buy | — | — | Reiterated | 2020-08-11 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2020-08-11 |
ALXO earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-27 | -0.38 | -0.42 | $0 | $0 |
| 2026-05-08 | -0.15 | -0.17 | $0 | $0 |
| 2026-08-06 | -0.14 | -0.13 | $0 | $0 |
| 2026-11-06 | -0.15 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.